News Category: Press Release

28 Dec 2015

Genomics England Selects LabKey for Integrated Data Management Solution

Genomics England has chosen the LabKey Server open source platform to provide its integrated data management solution. Genomics England will work with LabKey to design and develop a solution that will integrate and securely share complex clinical and genomic data for the 100,000 Genomes Project.

The 100,000 Genomes Project aims to sequence 100,000 whole genomes from approximately 70,000 people. Participants are NHS patients in the UK with certain types of cancer or with rare disease, as well as their families. The initiative will bring together an unprecedented depth of clinical and genomic information to improve prediction and prevention of disease, spur the development of new diagnostics, and support personalization of medical treatments based on genotypes. This is currently the largest national sequencing project of its kind in the world.

The LabKey solution will facilitate aggregation, review and integration of phenotype and genotype information across contributing labs, clinical sites and repositories. It will also enable review, reporting and analysis of this information by both clinicians and researchers, ensure protection of patient privacy, and support data de-identification and knowledge sharing.

Jim Davies, Chief Technology Officer of Genomics England explains, “By partnering with LabKey, we bring on board an excellent software platform and a technical team whose expertise in developing enterprise solutions for biomedical research and healthcare will significantly accelerate our efforts.

“We are excited to build on the rich foundation of LabKey Server. It is unique among tools in this field for its quality, extensibility, and reporting and analytical capabilities.”

“We see enormous potential for the work of Genomics England to benefit both patient care and research. We are proud and excited to be part of this innovative initiative,” adds Michael Gersch, CEO of LabKey Software.

“Building on the LabKey Server platform lets Genomics England leverage years of development with hundreds of research institutions and focus investment on incremental functionality needed beyond this proven base.”

About Genomics England

Genomics England is a company owned by the Department of Health and was set up to deliver the 100,000 Genomes Project. This flagship project will sequence 100,000 whole genomes from NHS patients and their families by 2017. Genomics England has four main aims:

  • to bring benefit to patients
  • to create an ethical and transparent programme based on consent
  • to enable new scientific discovery and medical insights
  • to kickstart the development of a UK genomics industry

The project is focusing on patients with rare diseases, and their families, as well as patients with common cancers.

15 Oct 2015

Genomics England Selects LabKey for Integrated Data Management Solution

Genomics England has chosen the LabKey Server open source platform to provide its integrated data management solution. Genomics England will work with LabKey to design and develop a solution that will integrate and securely share complex clinical and genomic data for the 100,000 Genomes Project.

The 100,000 Genomes Project aims to sequence 100,000 whole genomes from approximately 70,000 people. Participants are NHS patients in the UK with certain types of cancer or with rare disease, as well as their families. The initiative will bring together an unprecedented depth of clinical and genomic information to improve prediction and prevention of disease, spur the development of new diagnostics, and support personalization of medical treatments based on genotypes. This is currently the largest national sequencing project of its kind in the world.

The LabKey solution will facilitate aggregation, review and integration of phenotype and genotype information across contributing labs, clinical sites and repositories. It will also enable review, reporting and analysis of this information by both clinicians and researchers, ensure protection of patient privacy, and support data de-identification and knowledge sharing.

Jim Davies, Chief Technology Officer of Genomics England explains, “By partnering with LabKey, we bring on board an excellent software platform and a technical team whose expertise in developing enterprise solutions for biomedical research and healthcare will significantly accelerate our efforts.

“We are excited to build on the rich foundation of LabKey Server. It is unique among tools in this field for its quality, extensibility, and reporting and analytical capabilities.”

“We see enormous potential for the work of Genomics England to benefit both patient care and research. We are proud and excited to be part of this innovative initiative,” adds Michael Gersch, CEO of LabKey Software.

“Building on the LabKey Server platform lets Genomics England leverage years of development with hundreds of research institutions and focus investment on incremental functionality needed beyond this proven base.”

About Genomics England

Genomics England is a company owned by the Department of Health and was set up to deliver the 100,000 Genomes Project. This flagship project will sequence 100,000 whole genomes from NHS patients and their families by 2017. Genomics England has four main aims:

  • to bring benefit to patients
  • to create an ethical and transparent programme based on consent
  • to enable new scientific discovery and medical insights
  • to kickstart the development of a UK genomics industry

The project is focusing on patients with rare diseases, and their families, as well as patients with common cancers.

02 Sep 2015

LabKey Software Partners with Just Biotherapeutics, Inc.

New software product targets biotherapeutic research and development

Seattle, Washington

LabKey Software and Just Biotherapeutics, Inc. have signed a multi-year agreement to develop a new software product that helps biotechnology R&D teams produce more effective and affordable biotherapeutics by optimizing development processes.

The new solution will enable preclinical research groups to accelerate lab workflows, automate project tracking, and gain immediate insight into molecules, processes and resources. With data intelligence on hand, teams can focus on developing high-quality therapeutics instead of battling bottlenecks in data entry, integration and analysis.

“LabKey builds software solutions that help research scientists integrate, analyze and share biomedical data, speeding their efforts to treat and cure diseases. We’re thrilled to be working with a team focused on innovation in biotherapeutics,” says Michael Gersch, CEO of LabKey Software. “We are very impressed with the Just team and their inspiring vision of bringing biologic medicines to global markets. We’re delighted to partner with them on this new product.”

The two companies will design, develop and implement a LabKey Software product for biotherapeutics R&D development based on Just’s specifications and requirements. The product will also be available for other companies to use.

“Today’s software solutions aren’t geared toward the problems that Just and other companies are working to solve with large molecule development,” says Jim Thomas, CEO of Just. “This partnership and resulting innovative product will make it easier for companies to accelerate the development of biotherapeutics.”

About Just.

Founded in 2014, Just is led by an experienced team in the fields of protein, process and manufacturing sciences. The Just team came together to solve the scientific and technical hurdles that block access to life changing protein therapeutics; from the design of therapeutic molecules to the design of the manufacturing plants used to produce them. This will create value not only for the developing world, but for the developed world as well.

02 Sep 2015

LabKey Software Partners with Just Biotherapeutics, Inc.

New software product targets biotherapeutic research and development

Seattle, Washington

LabKey Software and Just Biotherapeutics, Inc. have signed a multi-year agreement to develop a new software product that helps biotechnology R&D teams produce more effective and affordable biotherapeutics by optimizing development processes.

The new solution will enable preclinical research groups to accelerate lab workflows, automate project tracking, and gain immediate insight into molecules, processes and resources. With data intelligence on hand, teams can focus on developing high-quality therapeutics instead of battling bottlenecks in data entry, integration and analysis.

“LabKey builds software solutions that help research scientists integrate, analyze and share biomedical data, speeding their efforts to treat and cure diseases. We’re thrilled to be working with a team focused on innovation in biotherapeutics,” says Michael Gersch, CEO of LabKey Software. “We are very impressed with the Just team and their inspiring vision of bringing biologic medicines to global markets. We’re delighted to partner with them on this new product.”

The two companies will design, develop and implement a LabKey Software product for biotherapeutics R&D development based on Just’s specifications and requirements. The product will also be available for other companies to use.

“Today’s software solutions aren’t geared toward the problems that Just and other companies are working to solve with large molecule development,” says Jim Thomas, CEO of Just. “This partnership and resulting innovative product will make it easier for companies to accelerate the development of biotherapeutics.”

About Just.

Founded in 2014, Just is led by an experienced team in the fields of protein, process and manufacturing sciences. The Just team came together to solve the scientific and technical hurdles that block access to life changing protein therapeutics; from the design of therapeutic molecules to the design of the manufacturing plants used to produce them. This will create value not only for the developing world, but for the developed world as well.

14 Apr 2015

LabKey Software Names Michael Gersch as CEO

Seattle business leader Michael Gersch joins LabKey Software as its new chief executive officer. LabKey is a fast-growing open source software company that helps scientists organize, analyze, and share biomedical research data.

Seattle, WA (via PRWEB) April 14, 2015

Seattle business leader Michael Gersch has joined LabKey Software as its new chief executive officer. LabKey Software is a fast-growing open-source software company that offers solutions to help scientists integrate, analyze, and share biomedical research data.

“Given our vision to build the best data platform for research scientists, we are fortunate to have a leader of Michael’s caliber,” says Randy Main, LabKey Software board member and chief financial officer at the Fred Hutchinson Cancer Research Center. “He has the experience and drive to scale LabKey to meet the steadily increasing demand for the company’s services and solutions,” he added.

Prior to joining LabKey Software, Gersch worked in leadership roles with a range of global software and technology companies, including ProQuest and LexisNexis. His background in growing small software groups into larger, customer-focused organizations means LabKey Software will become an even stronger partner for all current and future clients.

“I chose LabKey Software for the tremendous opportunity to scale the organization and meet the needs created by the rapid growth of scientific data and expansion in the collaborative nature of research,” says CEO Michael Gersch. I am extremely impressed by the LabKey team, and look forward to working together to affect positive change in the field of scientific research,” he added.

LabKey Software was founded 10 years ago as a spin-out from the Fred Hutchison Cancer Research Center. Its LabKey Server platform is flexible, scalable, and extensible, making it an ideal foundation for global research teams investigating complex diseases such as HIV/AIDS, cancer and malaria. LabKey solutions are designed to address each organization’s unique data sharing requirements, research protocols, analysis methods, and data sources. The company is growing at a fast pace and hiring for multiple positions.

LabKey partners include Fred Hutch, the HIV Vaccine Trial Network (HVTN), the Immune Tolerance Network (ITN), the Human Immunology Project Consortium (HIPC), pharmaceutical companies, and individual labs at Stanford University, Seattle Children’s Research Institute, and the University of Washington.

About LabKey Software
LabKey Software partners with biomedical research organizations to develop custom solutions that unlock the value of hard-earned data, enable collaborative science, and open doors to new modes of discovery. Teams use LabKey solutions to integrate, analyze and securely share complex research information while adapting to evolving needs. LabKey solutions build on the LabKey Server open source platform, so new users benefit from more than a decade of past investments and funders see their impact multiplied. LabKey Software originated at the Fred Hutchinson Cancer Research Center and has offices in Seattle and San Diego.

For the original version on PRWeb, visit: http://www.prweb.com/releases/2015/04/prweb12632364.htm

14 Apr 2015

LabKey Software Names Michael Gersch as CEO

Seattle business leader Michael Gersch joins LabKey Software as its new chief executive officer. LabKey is a fast-growing open source software company that helps scientists organize, analyze, and share biomedical research data.

Seattle, WA (via PRWEB) April 14, 2015

Seattle business leader Michael Gersch has joined LabKey Software as its new chief executive officer. LabKey Software is a fast-growing open-source software company that offers solutions to help scientists integrate, analyze, and share biomedical research data.

“Given our vision to build the best data platform for research scientists, we are fortunate to have a leader of Michael’s caliber,” says Randy Main, LabKey Software board member and chief financial officer at the Fred Hutchinson Cancer Research Center. “He has the experience and drive to scale LabKey to meet the steadily increasing demand for the company’s services and solutions,” he added.

Prior to joining LabKey Software, Gersch worked in leadership roles with a range of global software and technology companies, including ProQuest and LexisNexis. His background in growing small software groups into larger, customer-focused organizations means LabKey Software will become an even stronger partner for all current and future clients.

“I chose LabKey Software for the tremendous opportunity to scale the organization and meet the needs created by the rapid growth of scientific data and expansion in the collaborative nature of research,” says CEO Michael Gersch. I am extremely impressed by the LabKey team, and look forward to working together to affect positive change in the field of scientific research,” he added.

LabKey Software was founded 10 years ago as a spin-out from the Fred Hutchison Cancer Research Center. Its LabKey Server platform is flexible, scalable, and extensible, making it an ideal foundation for global research teams investigating complex diseases such as HIV/AIDS, cancer and malaria. LabKey solutions are designed to address each organization’s unique data sharing requirements, research protocols, analysis methods, and data sources. The company is growing at a fast pace and hiring for multiple positions.

LabKey partners include Fred Hutch, the HIV Vaccine Trial Network (HVTN), the Immune Tolerance Network (ITN), the Human Immunology Project Consortium (HIPC), pharmaceutical companies, and individual labs at Stanford University, Seattle Children’s Research Institute, and the University of Washington.

About LabKey Software
LabKey Software partners with biomedical research organizations to develop custom solutions that unlock the value of hard-earned data, enable collaborative science, and open doors to new modes of discovery. Teams use LabKey solutions to integrate, analyze and securely share complex research information while adapting to evolving needs. LabKey solutions build on the LabKey Server open source platform, so new users benefit from more than a decade of past investments and funders see their impact multiplied. LabKey Software originated at the Fred Hutchinson Cancer Research Center and has offices in Seattle and San Diego.

For the original version on PRWeb, visit: http://www.prweb.com/releases/2015/04/prweb12632364.htm

CONTACT US